Stem cell transplants prove more cost-effective than gene therapy for sickle cell disease

Sickle cell disease affects approximately 100,000 individuals in the United States and 8 million worldwide, causing severe pain, organ damage, and life-limiting complications.

For the roughly 100,000 Americans and 8 million people worldwide living with sickle cell disease, the arrival of gene therapy promised a new chapter — but a new economic analysis published in Blood suggests that promise carries a price the health system may not yet be able to bear. Researchers at Yale have found that stem cell transplantation, particularly a newer and more accessible form requiring only a half-matched donor, delivers substantially better value for money than gene therapy at current prices. The findings do not diminish gene therapy's clinical achievement, but they place it with

Stem cell transplants prove more cost-effective than gene therapy for sickle cell disease

Cobertura Relacionada

Recibe The Register en tu bandeja